Home  »  Company   »  After A 25.81% Jump In The Last Week, Does Infinit...

After A 25.81% Jump In The Last Week, Does Infinity Pharmaceuticals Inc. (NASDAQ: INFI) Still Make Sense To Buy?

During the last session, Infinity Pharmaceuticals Inc. (NASDAQ:INFI)’s traded shares were 0.41 million, with the beta value of the company hitting 2.05. At the end of the trading day, the stock’s price was $0.80, reflecting an intraday gain of 6.48% or $0.05. The 52-week high for the INFI share is $3.89, that puts it down -386.25 from that peak though still a striking 42.5% gain since the share price plummeted to a 52-week low of $0.46. The company’s market capitalization is $75.08M, and the average intraday trading volume over the past 10 days was 0.28 million shares, and the average trade volume was 693.63K shares over the past three months.

Infinity Pharmaceuticals Inc. (INFI) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.90. INFI has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.15.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) trade information

Infinity Pharmaceuticals Inc. (INFI) registered a 6.48% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.48% in intraday trading to $0.80 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 25.81%, and it has moved by 18.79% in 30 days. Based on these gigs, the overall price performance for the year is -73.34%. The short interest in Infinity Pharmaceuticals Inc. (NASDAQ:INFI) is 1.38 million shares and it means that shorts have 1.54 day(s) to cover.

The consensus price target of analysts on Wall Street is $5.30, which implies an increase of 84.91% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.00 and $11.00 respectively. As a result, INFI is trading at a discount of -1275.0% off the target high and -275.0% off the low.

Infinity Pharmaceuticals Inc. (INFI) estimates and forecasts

Statistics show that Infinity Pharmaceuticals Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Infinity Pharmaceuticals Inc. (INFI) shares have gone down -31.05% during the last six months, with a year-to-date growth rate less than the industry average at 1.89% against 11.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -15.40% this quarter and then drop -25.00% in the quarter after that. In the rating firms’ projections, revenue will increase 21.10% compared to the previous financial year.

Revenue for the current quarter is expected to be $520k as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $490k by the end of Sep 2022.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 2.70%. While earnings are projected to return 21.80% in 2022.

INFI Dividends

Infinity Pharmaceuticals Inc. is due to release its next quarterly earnings between March 14 and March 18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)’s Major holders

Infinity Pharmaceuticals Inc. insiders own 1.25% of total outstanding shares while institutional holders control 44.71%, with the float percentage being 45.28%. Blackrock Inc. is the largest shareholder of the company, while 129 institutions own stock in it. As of Mar 30, 2022, the company held over 6.57 million shares (or 7.37% of all shares), a total value of $7.49 million in shares.

The next largest institutional holding, with 6.35 million shares, is of BVF Inc.’s that is approximately 7.13% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $7.24 million.

Also, the Mutual Funds coming in first place with the largest holdings of Infinity Pharmaceuticals Inc. (INFI) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 2.52 million shares. This amounts to just over 2.82 percent of the company’s overall shares, with a $2.87 million market value. The same data shows that the other fund manager holds slightly less at 1.26 million, or about 1.41% of the stock, which is worth about $1.43 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]